Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.

Summary

Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical efficacy has been shown in adult with head and neck cancer. The study assessed the safety and efficacy of different dosage of Nimotuzumab in second or late- line treatment of patients with locally advanced or metastatic esophageal squamous cell carcinomas.

Timeline

Start

2013-08

Primary completion

2014-03

Completion

2014-06

Drugs

Indications